Rationale of hypoxic condition in Development of Liver Cancer
肝癌发生过程中缺氧的原理
基本信息
- 批准号:12670901
- 负责人:
- 金额:$ 2.05万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2000
- 资助国家:日本
- 起止时间:2000 至 2002
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The liver is one of the most hypoxia-sensitive and hypoxic organs because of the energy consumptive cellular functions and that the 80% of the blood supply is portal venous flow. The most human liver cancer is known arising from the chronic hepatitis base or cirrhotic base. And several experimental liver cancers in the rat develop among inflammatory regenerative process.In the present experiment carcinogenetic model applied to Wister rat did not show any evidence of carcinogenesis with repeated injection of CCl4. Instead of the expected carcinogenic process they showed a course of inflammatory reaction and fibrotic reaction that was a common process with the liver cirrhosis. The inflammatory course showed transient hypoxia in the liver parenchyma bottomed at the 4^<th> week followed by V-shaped rebound while the CCl4 was still administrated. Then the rebound was not because the toxin (CCl4) was ceased but supposedly because due to tissue reaction including repairing process such as angiogenesis. This was coincided with the fact that, in the molecular research, this hypoxia was reflected to increase of the HIF1alpha. In the control group and a group in which CCl4 and anti-inflammatory drug (a cox-2 inhibitor) group showed less intensive hypoxia, and the less intensive induction of the HIF1alpha, correspondingly. Though this observation is very limited but is suggesting that inflammatory process involved in carcinogenic condition and that hypoxia is related to severity of inflammation. This also suggest a possibility of a hypothesis that anti-inflammatory drug (especially, cox-2 inhibitor) may be useful in reducing the cancer induction though hypoxic process in the liver. This project will be succeeded with a new budget by the same head investigator.
肝脏是对缺氧最敏感和缺氧的器官之一,因为肝脏具有消耗能量的细胞功能,并且80%的血液供应是门静脉血流。已知大多数人类肝癌源自慢性肝炎或肝硬化。大鼠中的几种实验性肝癌是在炎症再生过程中发生的。在目前应用于Wister大鼠的致癌模型中,没有显示出任何重复注射CCl4的致癌证据。他们没有表现出预期的致癌过程,而是表现出炎症反应和纤维化反应过程,这是肝硬化的常见过程。炎症过程显示肝实质短暂缺氧,在第4周触底,随后在仍施用CCl 4 时出现V形反弹。那么反弹并不是因为毒素(CCl4)停止,而是因为组织反应,包括血管生成等修复过程。这与分子研究中这种缺氧反映为HIF1α的增加这一事实相吻合。在对照组和CCl4和抗炎药(cox-2抑制剂)组中,缺氧程度较低,HIF1α的诱导程度也相应较低。尽管这一观察结果非常有限,但表明炎症过程涉及致癌情况,并且缺氧与炎症的严重程度有关。这也表明抗炎药(特别是cox-2抑制剂)可能有助于通过肝脏缺氧过程减少癌症诱导的假设。该项目将由同一位首席研究员通过新的预算来完成。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Li X, Feng GS, Zheng CS, Zhuo OK, Liu X.: "Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma : an experimental
李X,冯国盛,郑CS,卓OK,刘X.:“经动脉化疗栓塞对Walker-256移植性肝癌大鼠血管生成及血管内皮生长因子和碱性成纤维细胞生长因子表达的影响:实验
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, Tofilon PJ, Milas L: "Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor"Cancer Res. 60. 1326-1331 (2000)
Kishi K、Petersen S、Petersen C、Hunter N、Mason K、Masferrer JL、Tofilon PJ、Milas L:“环氧合酶 2 抑制剂优先增强肿瘤放射反应”Cancer Res。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Sato M, Kawai N, Iwamoto T, Ishii S, Nakai M, Masuda M, Takeuchi T, Tanihata H, Terada M, Kishi K: "Current status of hepatocellular carcinoma and percutaneous hot ethanol injection therapy"Japanese Journal of Hyperthermic Onocology. 16. 9-15 (2000)
Sato M、Kawai N、Iwamoto T、Ishii S、Nakai M、Masuda M、Takeuchi T、Tanihata H、Terada M、Kishi K:“肝细胞癌和经皮热乙醇注射治疗的现状”日本热肿瘤学杂志。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kim YB, Park YN, Park C.: "Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization"Histopathology. 38(2). 160-166 (2001)
Kim YB、Park YN、Park C.:“经导管动脉栓塞后残余肝细胞癌中血管内皮细胞和肿瘤细胞的增殖活性增加”组织病理学。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kishi K, Milas L, Hunter N, Sao M.: "Antiangiogenetic therapy to the cancer"Nihon Rinsho (Japanese review). 58(8). 1747-1762 (2000)
Kishi K、Milas L、Hunter N、Sao M.:“癌症的抗血管生成疗法”Nihon Rinsho(日本评论)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KISHI Kazushi其他文献
KISHI Kazushi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
NK细胞通过CCL4/5-CCR4/5轴募集cDC1至肿瘤微环境介导PolySTING抗结直肠癌作用机制研究
- 批准号:82373279
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
肝细胞源性CCL4通过调控NLRP3/GSDMD介导的巨噬细胞焦亡加重肝脏缺血再灌注损伤的机制研究
- 批准号:82300724
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
TACC2通过上调趋化因子CCL3/CCL4增强软组织肉瘤抗肿瘤免疫的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
CCL4调控肿瘤浸润Tregs表型与功能影响EGFR-TKI获得性耐药非小细胞肺癌抗PD-1/PD-L1疗效的机制
- 批准号:82203004
- 批准年份:2022
- 资助金额:20 万元
- 项目类别:青年科学基金项目
四氯化碳厌氧生物降解机制及微生物与矿物协同强化去除研究
- 批准号:41907287
- 批准年份:2019
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PREVENTING ALZHEIMER’S DISEASE-LIKE BRAIN PATHOLOGY IN HIV INFECTION BY TARGETING CCR5
通过靶向 CCR5 预防 HIV 感染中的阿尔茨海默病样脑部病变
- 批准号:
10700624 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Drugs repositioning to target TREM2 in Alzheimer disease
药物重新定位以治疗阿尔茨海默病中的 TREM2
- 批准号:
10639456 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Developing a new bispecific antibody mimicking rapid antigen-specific memory CD8+ T cell-mediated protection
开发一种新型双特异性抗体,模仿快速抗原特异性记忆 CD8 T 细胞介导的保护
- 批准号:
10742118 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Prostaglandin D2 and its receptor CRTH2 regulate intestinal inflammation and homeostasis
前列腺素 D2 及其受体 CRTH2 调节肠道炎症和体内平衡
- 批准号:
10733671 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别:
Molecular Mechanisms Associated with Insomnia and Response to Cognitive Behavioral Therapy for Insomnia
与失眠相关的分子机制以及对失眠认知行为疗法的反应
- 批准号:
10590036 - 财政年份:2023
- 资助金额:
$ 2.05万 - 项目类别: